Patents by Inventor Stefan Somlo
Stefan Somlo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250082663Abstract: The present invention provides methods for treating or preventing Autosomal Dominant Polycystic Kidney Disease (ADPKD) and/or Autosomal Dominant Polycystic Liver Disease (ADPLD) and/or Autosomal Recessive Polycystic Kidney Disease (ARPKD) in a mammal.Type: ApplicationFiled: June 14, 2022Publication date: March 13, 2025Inventors: Matteus KRAPPITZ, Sorin FEDELES, Stefan SOMLO
-
Publication number: 20180362574Abstract: The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.Type: ApplicationFiled: April 13, 2018Publication date: December 20, 2018Applicants: Massachusetts Institute of Technology, Yale UniversityInventors: Bogdan I. Fedeles, Sorin V. Fedeles, Robert G. Croy, Stefan Somlo, John M. Essigmann
-
Patent number: 9982009Abstract: The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.Type: GrantFiled: October 15, 2014Date of Patent: May 29, 2018Assignees: Massachusetts Institute of Technology, Yale UniversityInventors: Bogdan I. Fedeles, Sorin V. Fedeles, Robert G. Croy, Stefan Somlo, John M. Essigmann
-
Publication number: 20150105361Abstract: The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell.Type: ApplicationFiled: October 15, 2014Publication date: April 16, 2015Applicants: Massachusetts Institute of Technology, Yale UniversityInventors: Bogdan I. Fedeles, Sorin V. Fedeles, Robert G. Croy, Stefan Somlo, John M. Essigmann
-
Publication number: 20080188449Abstract: In certain aspects, the invention relates to use of PKD2 agonists, such as triptolide and triptolide derivatives, to regulate calcium release. In other aspects, the invention relates to use of PKD2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the gene product of PKD 1 and/or PKD2, is mutated; calcium signaling is abnormal; or both, such as polycystic kidney disease.Type: ApplicationFiled: November 15, 2005Publication date: August 7, 2008Applicant: Yale UniversityInventors: Craig M. Crews, Stephanie J. Quinn, Stefan Somlo, Dayne Okuhara
-
Publication number: 20080063601Abstract: Described herein are therapeutic strategies (methods and compositions) useful for treating conditions in which cilia are affected and which manifest with cysts and/or fibrosis, such as conditions in which the kidney, pancreas, liver and/or spleen are affected and contain cysts. Particular embodiments described herein are therapeutic strategies in which PC-2 agonists, particularly agonists (calcium channel agonists) that target PC-2 directly and/or selectively, are administered to individuals with mutations in PKD1, in order to alter the course of polycystic kidney disease, particularly ADPKD. In specific embodiments, the invention relates to use of PC-2 agonists triptolide and triptolide derivatives to regulate calcium release. In other aspects, the invention relates to use of PC-2 agonists to treat or aid in the treatment of any condition in which a calcium channel, such as the gene product of PKD1 and/or PKD2, is mutated; calcium signaling is abnormal; or both.Type: ApplicationFiled: March 12, 2007Publication date: March 13, 2008Applicant: Yale UniversityInventors: Stefan Somlo, Craig Crews, Stephanie Quinn, Dayne Okuhara
-
Publication number: 20080057506Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.Type: ApplicationFiled: June 26, 2007Publication date: March 6, 2008Inventors: Stefan Somlo, Toshio Mochizuki
-
Patent number: 7294465Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.Type: GrantFiled: January 21, 2005Date of Patent: November 13, 2007Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Stefan Somlo, Toshio Mochizuki
-
Patent number: 7083915Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.Type: GrantFiled: January 2, 2001Date of Patent: August 1, 2006Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Stefan Somlo, Toshio Mochizuki
-
Publication number: 20050170399Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.Type: ApplicationFiled: January 21, 2005Publication date: August 4, 2005Inventors: Stefan Somlo, Toshio Mochizuki
-
Publication number: 20020061520Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.Type: ApplicationFiled: January 2, 2001Publication date: May 23, 2002Inventors: Stefan Somlo, Toshio Mochizuki
-
Patent number: 6228591Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.Type: GrantFiled: August 30, 1999Date of Patent: May 8, 2001Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Stefan Somlo, Toshio Mochizuki
-
Patent number: 6031088Abstract: The present invention provides a purified and isolated wild type PKD2 gene, as well as mutated forms of this gene. The present invention also provides one or more single-stranded nucleic acid probes which specifically hybridize to the wild type PKD2 gene or the mutated PKD2 gene, and mixtures thereof, which may be formulated in kits, and used in the diagnosis of ADPKD associated with the mutated PKD2 gene. The present invention also provides a method for diagnosing ADPKD caused by a mutated PKD2 gene, as well as a method for treating autosomal dominant polycystic kidney disease caused by a mutated PKD2 gene.Type: GrantFiled: May 23, 1996Date of Patent: February 29, 2000Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Stefan Somlo, Toshio Mochizuki